Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel

Inclusion Criteria

• •The subject has a solid tumor. Expansion cohorts are limited to non-small cell lung cancer and/or pancreatic cancer with or without a KRAS mutation.
• •Tumor progression following at least one prior standard therapy, the subject refuses standard therapy, or no standard therapy exists.
• •The subject has a radiographically measurable tumor.
• •The subject is able to carry out daily life activities without difficulty.
• •The subject is able to swallow and retain oral medication.
• •The subject does not have significant side effects from previous anti-cancer treatment.
• •The subject has adequate organ and blood cell counts.
• •Sexually active subjects must use medically acceptable methods of contraception during the course of the study.